Oncology Products

Highlight

• First local Bevacizumab produce in Indonesia
• First line treatment in multi indications
• Affordable price

Indication

Metastatic Colorectal Cancer (mCRC), advanced/metastatic/recurrent Non-Small Cell Lung Cancer (NSCLC), locally recurrent or metastatic triple-negative Breast Cancer (mBC), epithelial ovarian, fallopian tube and primary peritoneal cancer, cervical cancer.

Specification:

• Form: Concentrate for solution for infusion
• Strength: 100 mg / 4 mL
• Pack: Box, 1 Vial @ 4 mL
• REG. BPOM: DKL2457901749A1
• Halal: ✓ Halal-certified
• Approvals: First local Bevacizumab in Indonesia

Highlight

• Based on clinical trials such as SEQUOIA and ALPINE, BRUKINSA demonstrates superior progression-free survival (PFS) compared to chemoimmunotherapy and first-generation BTK inhibitors.
• ⁠It exhibits a manageable safety profile in both elderly and younger adult patients, offering long-term efficacy, including in patients with genetic mutations such as Del 17p.
• Designed for high tolerability with minimal side effects.

Indication

Mantle Cell Lymphoma (MCL); Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL); Marginal Zone Lymphoma (MZL); Follicular Lymphoma (FL); Waldenstrom's Macroglobulinemia (WM).

Specification:

• Form: Capsules
• Strength: 80 mg
• Pack: Box, 120 Capsules
• REG. BPOM: DKI2468000201A1
• Approvals: NCCN Guidelines recommended

Highlight

• Etapidi demonstrated clinical benefit regardless of PD-L1 expression
• A promising PD-1 inhibitor approved in Indonesia
• Has been approved in over 40 countries, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

Indication

Non-Small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer/gastroesophageal junction (GC/GEJ)

Specification:

• Form: Concentrate solution for IV infusion
• Strength: 100 mg / 10 mL
• Pack: Box, 1 Vial @ 10 mL
• REG. BPOM: DKI2468600149A1
• Approvals: US FDA · EMA · 40+ countries

Highlight

• Firstline treatment for EGFR mutation NSCLC
• Affordable Price
• Listed in E-Catalogue

Indication

Gefitinib for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

Specification:

• Form: Film-coated tablets
• Strength: 250 mg
• Pack: Box, 3 blisters @ 10 film-coated tablets
• REG. BPOM: DKI2365600217A1
• E-Catalogue: Listed

Highlight

• Irreversible pan-HER2 inhibitor for enhanced efficacy
• Additional recurrence risk reduction beyond trastuzumab-based therapy
• Convenient once-daily oral targeted therapy (Tyrosine Kinase Inhibitor - TKI)

Indication

As a single agent for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following trastuzumab-based therapy; and in combination with capecitabine for the treatment of adults with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

Specification:

• Form: Film-coated tablets
• Strength: 40 mg
• Pack: Box, 1 Bottle @ 180 film-coated tablets
• REG. BPOM: DKI2570500117A1

Highlight

• First line treatment in HER2-positive breast cancer
• Has been approved in over 100 countries
• Approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

Indication

HER2-positive Early Breast Cancer (eBC), HER2-positive Metastatic Breast Cancer (mBC), and HER2-positive Metastatic Gastric Cancer (mGC).

Specification:

• Form: Powder for concentrate, IV infusion
• Strength: 440 mg
• Pack: 1 Vial
• BPOM: DKI2554100644A1
• Approvals: US FDA · EMA · 100+ countries

Highlight

• The first rituximab biosimilar approved by the US FDA
• Has been approved in over 40 countries
• Approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
• CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL), CD20-positive B-cell Chronic Lymphocytic Leukemia (CLL).

Indication

Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukaemia (CLL).

Specification:

• Form: Concentrate solution for IV infusion
• Strength: 100 mg / 10 mL · 500 mg / 50 mL
• Pack: 1 Vial
• REG. BPOM: DKI2454100549A1
• Halal: ✓ Halal-certified
• Approvals: US FDA · EMA · 40+ countries

Highlight

• Potent third-generation bisphosphonate
• High affinity to bone (long duration of action)
• Reduces risk of skeletal-related events (fractures, spinal compression)
• Effective in both oncology & metabolic bone diseases
• Convenient IV administration (once yearly /periodic dosing)

Indication

Bone metastases from solid tumors; hypercalcemia of malignancy; multiple myeloma; treatment and prevention of osteoporosis (postmenopausal & male); glucocorticoid-induced osteoporosis; Paget's disease of bone.

Specification:

• Form: Solution for IV injection
• Strength: 0.8 mg / mL
• Pack: 1 Vial @ 5 mL
• REG. BPOM: GKL2557902149A1
• BPJS: Listed